Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
57.24
+1.12 (2.00%)
Apr 8, 2026, 11:29 AM CST
SHA:600276 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 40,955 | 24,816 | 20,746 | 15,111 | 13,631 |
Trading Asset Securities | 113.84 | 273.34 | 99.05 | 2,760 | 5,090 |
Cash & Short-Term Investments | 41,069 | 25,089 | 20,845 | 17,871 | 18,721 |
Cash Growth | 63.69% | 20.36% | 16.64% | -4.54% | 13.93% |
Accounts Receivable | 5,909 | 6,159 | 6,135 | 8,341 | 6,884 |
Other Receivables | 28.17 | 66.41 | 438.25 | 562.18 | 658 |
Receivables | 5,938 | 6,226 | 6,573 | 8,904 | 7,542 |
Inventory | 2,878 | 2,417 | 2,314 | 2,451 | 2,403 |
Prepaid Expenses | 166.79 | 239.54 | 226.07 | 507.2 | 431.57 |
Other Current Assets | 1,438 | 1,343 | 1,329 | 1,201 | 1,090 |
Total Current Assets | 51,490 | 35,315 | 31,287 | 30,934 | 30,188 |
Property, Plant & Equipment | 7,908 | 6,928 | 6,629 | 6,676 | 6,276 |
Long-Term Investments | 2,030 | 1,732 | 1,451 | 1,508 | 1,001 |
Other Intangible Assets | 1,956 | 1,192 | 883.77 | 519.9 | 442.45 |
Long-Term Deferred Tax Assets | 780.96 | 377.17 | 320.56 | 238.9 | 141.36 |
Long-Term Deferred Charges | 5,090 | 4,112 | 2,829 | 2,052 | 569.38 |
Other Long-Term Assets | 611.69 | 479.11 | 383.3 | 442.55 | 648.99 |
Total Assets | 69,867 | 50,136 | 43,785 | 42,371 | 39,266 |
Accounts Payable | 1,995 | 1,517 | 1,334 | 1,493 | 1,920 |
Accrued Expenses | 1,405 | 941.05 | 578.85 | 97.57 | 165.66 |
Short-Term Debt | - | - | - | 1,261 | - |
Current Portion of Leases | 30.93 | 41.13 | - | - | - |
Current Income Taxes Payable | 633.05 | 242.94 | 59.28 | 4.03 | 21.77 |
Current Unearned Revenue | 1,913 | 159.79 | 198.09 | 187.08 | 219.55 |
Other Current Liabilities | 392.96 | 731.36 | 383.42 | 596.13 | 1,074 |
Total Current Liabilities | 6,369 | 3,634 | 2,554 | 3,639 | 3,402 |
Long-Term Leases | 43.31 | 69.04 | 75.18 | 98.86 | 151.59 |
Long-Term Unearned Revenue | 1,541 | 225.65 | 38.95 | 119.44 | 116.52 |
Long-Term Deferred Tax Liabilities | 116.96 | 117.11 | 83.64 | 100.45 | 24.77 |
Total Liabilities | 8,070 | 4,045 | 2,751 | 3,958 | 3,694 |
Common Stock | 6,637 | 6,379 | 6,379 | 6,379 | 6,396 |
Additional Paid-In Capital | 12,935 | 3,188 | 3,058 | 3,020 | 3,356 |
Retained Earnings | 43,601 | 37,164 | 32,102 | 28,819 | 25,928 |
Treasury Stock | -1,929 | -1,229 | -1,092 | -398.03 | -664.94 |
Comprehensive Income & Other | 27.96 | 16.97 | 19.32 | 3.23 | -12.16 |
Total Common Equity | 61,272 | 45,520 | 40,466 | 37,824 | 35,003 |
Minority Interest | 524.75 | 570.39 | 567.29 | 589.35 | 568.85 |
Shareholders' Equity | 61,797 | 46,090 | 41,033 | 38,413 | 35,572 |
Total Liabilities & Equity | 69,867 | 50,136 | 43,785 | 42,371 | 39,266 |
Total Debt | 74.23 | 110.16 | 75.18 | 1,360 | 151.59 |
Net Cash (Debt) | 40,995 | 24,979 | 20,770 | 16,511 | 18,570 |
Net Cash Growth | 64.12% | 20.27% | 25.79% | -11.08% | 13.00% |
Net Cash Per Share | 6.27 | 3.94 | 3.28 | 2.58 | 2.91 |
Filing Date Shares Outstanding | 6,534 | 6,362 | 6,361 | 6,367 | 6,382 |
Total Common Shares Outstanding | 6,534 | 6,362 | 6,361 | 6,367 | 6,382 |
Working Capital | 45,121 | 31,681 | 28,734 | 27,295 | 26,786 |
Book Value Per Share | 9.38 | 7.16 | 6.36 | 5.94 | 5.48 |
Tangible Book Value | 59,316 | 44,328 | 39,582 | 37,304 | 34,561 |
Tangible Book Value Per Share | 9.08 | 6.97 | 6.22 | 5.86 | 5.42 |
Buildings | 4,892 | 3,975 | 3,854 | 3,541 | 2,700 |
Machinery | 6,523 | 6,104 | 5,969 | 5,684 | 5,120 |
Construction In Progress | 2,006 | 1,688 | 1,101 | 1,193 | 1,659 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.